PerkinElmer Stock Earns 83 Relative Strength Rating; Buys Lifescience Firm BioLegend

One important metric to look for in a stock is an 80 or higher Relative Strength Rating. PerkinElmer (PKI) just hit that mark, with a jump from 80 to 83 Tuesday.

The diagnostic, life science and food company said it would buy BioLegend, a privately held maker of of biomedical research tools for Covid-19 and other illnesses, in a deal worth $5.25 billion in shares and cash.


When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

IBD’s unique RS Rating identifies market leadership by showing how a stock’s price movement over the last 52 weeks measures up against that of other stocks on the major indexes.

Over 100 years of market history shows that the best-performing stocks typically have an 80 or better RS Rating in the early stages of their moves.

Looking For Winning Stocks? Try This Simple Routine

Is PerkinElmer Stock A Buy?

PerkinElmer stock is now considered extended and out of buy range after clearing a 149.19 buy point in a first-stage cup with handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average. Read “Looking For The Next Big Stock Market Winners? Start With These 3 Steps” for more tips.


The company reported 80% EPS growth in its most recent report, while sales growth came in at 51%.

PerkinElmer stock holds the No. 6 rank among its peers in the Medical-Research Equipment/Services industry group. Avantor (AVTR) and Iqvia (IQV) are also among the group’s highest-rated stocks.


MarketSmith’s Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks

Most Related Links :
reporterwings Governmental News Finance News

Source link

Back to top button